CytomX TherapeuticsCTMX -0.15%36 Piotroski F-Score is 2 as of Jun. 25, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,342 Biotechnology companies, CytomX Therapeutics ranks worse than 73.25% on this metric.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
CytomX Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for CytomX Therapeutics's Piotroski F-Score or its related term are showing as below:
CTMX'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 3 Max: 6
Current: 2
During the past 13 years, the highest Piotroski F-Score of CytomX Therapeutics was 6. The lowest was 1. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
CytomX Therapeutics Piotroski F-Score Related Terms
CytomX Therapeutics Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTMX vs SMNR, AURA, OMER: Piotroski F-Score Comparison
For the Biotechnology subindustry, CytomX Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
CytomX Therapeutics's current Net Income (TTM) was -59.14.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
CytomX Therapeutics's return on assets of this year was -0.60043453. CytomX Therapeutics's return on assets of last year was 0.2252622.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
CytomX Therapeutics's gearing of this year was 0. CytomX Therapeutics's gearing of last year was 0.02034429.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
CytomX Therapeutics's current ratio of this year was 10.37815595. CytomX Therapeutics's current ratio of last year was 1.725623.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
CytomX Therapeutics's number of shares in issue this year was 177.273. CytomX Therapeutics's number of shares in issue last year was 87.151.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
CytomX Therapeutics's gross margin of this year was 1. CytomX Therapeutics's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
CytomX Therapeutics's asset turnover of this year was 0.36084348. CytomX Therapeutics's asset turnover of last year was 0.79895715.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
0
+
1
+
1
+
0
+
0
+
0
=
2
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
CytomX Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
CytomX Therapeutics (CTMX) has a Piotroski F-Score of 2 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CytomX Therapeutics and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, CytomX Therapeutics' Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, CytomX Therapeutics ranks #983 out of 1342 companies in the Biotechnology industry, placing it in the top 73.2%.
Is CytomX Therapeutics' Piotroski F-Score too high?
CytomX Therapeutics' current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. CytomX Therapeutics' value of 2 is 33.3% below this industry median. Based on the distribution chart, CytomX Therapeutics ranks #983 out of 1342 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Piotroski F-Score compare to SMNR and AURA?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #983 out of 1342 companies for Piotroski F-Score. This places CytomX Therapeutics in the lower half of its industry. The industry median Piotroski F-Score is 3.00. CytomX Therapeutics' value of 2 is 33.3% below this benchmark. Historically, CytomX Therapeutics' own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, CytomX Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on CytomX Therapeutics and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.32 — trading 1083.9% above its estimated fair value. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Piotroski F-Score is 2 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.32 is trading 1083.9% above its estimated GF Value™ of $0.28.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Piotroski F-Score: 2 (33% below median its 10-year median of 3.00)
GF Value™: $0.28 vs. price of $3.32 (1083.9% above fair value)
Industry Position: 33.3% below the Biotechnology median (#983 of 1342)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score
Get the complete analysis for CTMX
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
